Previous 10 | Next 10 |
Sonoma Pharmaceuticals (SNOA) +28% on agreement with EMC pharma.Future FinTech Group (FTFT) +24% on acquiring bitcoin mining farm.AeroCentury (ACY) +22%.Jaguar Health (JAGX) +19% on FY results.P&F Industries (PFIN) +21%.AgEagle Aerial Systems (UAVS) +19% on FY results....
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) -- A...
Arbutus Biopharma (ABUS) announces that it has received regulatory approval to initiate a Phase 1a/1b clinical trial with AB-836, its proprietary oral capsid inhibitor for the treatment of HBV infection. Hepatitis B is a potentially life-threatening liver infection caused by HB...
WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (in...
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2020 Earnings Call Mar 04, 2021 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) Q4 2020 Earnings Conference Call March 4, 2021 8:45 a.m. ET Company Participants Pam Murphy - IR Bill Collier - President and CEO Gaston Picchio - Chief Development Officer Mike Sofia - Chief Scientific Officer Dave Hastings - CFO Conference Call Participa...
The following slide deck was published by Arbutus Biopharma Corporation in conjunction with their 2020 Q4 earnings call. For further details see: Arbutus Biopharma Corporation 2020 Q4 - Results - Earnings Call Presentation
Arbutus Biopharma (ABUS): FY GAAP EPS of -$1.00 misses by $0.01.Revenue of $6.91M (+15.0% Y/Y) beats by $0.31M.Shares -1.1% PM.Press Release For further details see: Arbutus Biopharma EPS misses by $0.01, beats on revenue
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data Reductions in HBsAg seen i...
WARMINSTER, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includi...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...